Article
Biochemistry & Molecular Biology
Alina Frey, Daniel Martin, Louisa D'Cruz, Emmanouil Fokas, Claus Rodel, Maximilian Fleischmann
Summary: The study assessed the C-reactive protein (CRP) to albumin ratio (CAR) as a prognostic score in locally advanced non-small-cell lung cancer (NSCLC) patients treated with CRT. The findings showed that elevated CAR was associated with worse outcomes, including poorer local control and shorter survival.
Article
Oncology
Koji Teramoto, Tomoyuki Igarashi, Yoko Kataoka, Mitsuaki Ishida, Jun Hanaoka, Hidetoshi Sumimoto, Yataro Daigo
Summary: PD-L1 expression on tumor cells is induced by interferon-gamma, suggesting the induction of an anti-tumor immune response. However, the clinical significance of PD-L1 expression may vary with tumor progression in NSCLC. High tumor PD-L1 expression status in early-stage NSCLC predicts good prognosis after radical surgery, while in locally advanced stage NSCLC, it may predict the incidence of postoperative tumor recurrence.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Tao Zhang, Wenji Xue, Daquan Wang, Kunpeng Xu, Linfang Wu, Yuqi Wu, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Jun Liang, Zefen Xiao, Zhouguang Hui, Jima Lv, Xin Wang, Lei Deng, Wenqing Wang, Wenyang Liu, Jianyang Wang, Yirui Zhai, Jie Wang, Nan Bi, Luhua Wang
Summary: Baseline lung immune prognostic index (LIPI) may serve as a potential prognostic biomarker for unresectable locally advanced lung cancer, with inferior outcomes in patients with intermediate-poor LIPI. Further prospective studies are needed to validate the potential of LIPI in patients with locally advanced lung cancer.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Stephanie P. L. Saw, Win Pin Ng, Siqin Zhou, Gillianne G. Y. Lai, Aaron C. Tan, Mei -Kim Ang, Wan-Teck Lim, Ravindran Kanesvaran, Quan Sing Ng, Amit Jain, Wan Ling Tan, Tanujaa Rajasekaran, Johan W. K. Chan, Yi Lin Teh, Mengyuan Pang, Jia-Chi Yeo, Angela Takano, Boon-Hean Ong, Eng-Huat Tan, Sze Huey Tan, Anders J. Skanderup, Daniel S. W. Tan
Summary: The aim of this study was to compare the prognostic value of programmed death-ligand 1 (PD-L1) score in early-stage epidermal growth factor receptor (EGFR)-mutated and EGFR-wildtype non-small cell lung cancer (NSCLC). The results showed that PD-L1 > 1% was an independent predictor of worse prognosis in EGFR-mutated NSCLC and was associated with inferior disease-free survival (DFS) regardless of EGFR status. Therefore, PD-L1 score should be evaluated as a risk stratification factor in prospective adjuvant studies among EGFR-mutated NSCLC.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Bochen Sun, Qing Hou, Yu Liang, Shuqin Xue, Ningning Yao, Lijuan Wei, Xin Cao, Hongwei Li, Hongwei Si, Jianzhong Cao
Summary: The study aimed to evaluate the role of LIPI in limited-stage SCLC and found that high-risk LIPI was associated with poorer overall survival and progression-free survival. A predictive nomogram based on LIPI was developed with decent predictive power.
Article
Oncology
Angelina Tjokrowidjaja, Sarah J. Lord, Thomas John, Craig R. Lewis, Peey-Sei Kok, Ian C. Marschner, Chee K. Lee
Summary: This study explores the prognostic and predictive value of lactate dehydrogenase (LDH) in advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). The findings suggest that elevated pretreatment LDH is associated with worse prognosis, regardless of treatment. Persistently elevated on-treatment LDH is also associated with decreased overall survival (OS) rates.
Article
Oncology
Lei Gong, Ronghui He, Yanjun Xu, Taobo Luo, Kaixiu Jin, Wuzhou Yuan, Zengguang Zheng, Lanxuan Liu, Zebin Liang, Ao Li, Zhiguo Zheng, Hui Li
Summary: In Chinese patients, higher neoantigen load (NAL) was associated with improved disease-free survival (DFS) in squamous cell lung carcinoma (SCC) patients, but not in lung adenocarcinoma (ADC) patients. A benefit from adjuvant chemotherapy was correlated with lower NAL. Other genomic factors did not show prognostic or predictive value for DFS in SCC or ADC patients.
Article
Oncology
Hallgeir Selven, Lill-Tove Rasmussen Busund, Sigve Andersen, Mona Irene Pedersen, Ana Paola Giometti Lombardi, Thomas Karsten Kilvaer
Summary: This study investigated the expression of protein biomarkers in stromal and tumor tissue of colon cancer patients. High expression of IRS1 in stromal tissue and RUNX3 and SMAD4 in both stromal and tumor tissue were associated with better prognosis. Particularly, the expression of RUNX3 in stromal tissue was correlated with the density of tumor-infiltrating lymphocytes. This finding has implications for understanding the role of lymphocytes in prognosis and improving immunotherapy effectiveness in colon cancer.
Article
Oncology
Busra Gul, Selma Metintas, Guntulu Ak, Senay Yilmaz, Muzaffer Metintas
Summary: The study aimed to identify factors related to poor nutritional status and its impact on the prognosis of patients with locally advanced and advanced stage lung cancer. Poor nutritional status was associated with age, gender, performance status, and BMI for NSCLC, and performance status for SCLC. Poor nutritional status significantly decreased overall survival in both NSCLC and SCLC populations.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Respiratory System
Tithi Biswas, Rohin Gawdi, Charulata Jindal, Sharanya Iyer, Kylie H. Kang, David Bajor, Mitchell Machtay, Yuk Ming Choi, Jimmy T. Efird
Summary: NLR is an important inflammation-based prognostic marker for survival in patients with locally advanced non-small cell lung cancer (NSCLC) undergoing chemoradiation, as shown in a study analyzing data from a randomized phase III clinical trial. Further research on the prognostic potential of NLR in relation to genetic mutations and molecular markers is warranted.
JOURNAL OF THORACIC DISEASE
(2021)
Article
Oncology
Sarah M. H. Einerhand, Nick van Dijk, Jeroen van Dorp, Jeantine M. de Feijter, Maurits L. van Montfoort, Maaike W. van de Kamp, Eva E. Schaake, Thierry N. Boellaard, Kees Hendricksen, Michiel S. van der Heijden, Bas W. G. van Rhijn
Summary: This study compared the clinical outcomes of neoadjuvant/induction platinum-based combination chemotherapy (NAIC) with combination immune checkpoint inhibition (cICI) in patients with locally advanced urothelial carcinoma. The results showed that cICI was associated with superior progression-free survival and overall survival compared to NAIC. This provides a strong rationale for validating cICI as the standard treatment for locally advanced urothelial carcinoma.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Silvia Waldeck, Jan Mitschke, Sebastian Wiesemann, Michael Rassner, Geoffroy Andrieux, Max Deuter, Jurik Mutter, Anne-Marie Luechtenborg, Daniel Kottmann, Laurin Titze, Christoph Zeisel, Martina Jolic, Ulrike Philipp, Silke Lassmann, Peter Bronsert, Christine Greil, Justyna Rawluk, Heiko Becker, Lisa Isbell, Alexandra Mueller, Soroush Doostkam, Bernward Passlick, Melanie Boerries, Justus Duyster, Julius Wehrle, Florian Scherer, Nikolas von Bubnoff
Summary: The study revealed that intraoperative plasma sampling in early-stage and locally advanced NSCLC patients results in high ctDNA detection rates, and early postoperative ctDNA positivity serves as a prognostic indicator of disease relapse.
MOLECULAR ONCOLOGY
(2022)
Article
Otorhinolaryngology
Natalia Martins Magacho de Andrade, Rogerio Aparecido Dedivitis, Daniel Marin Ramos, Leandro Luongo Matos, Marcio Ricardo Taveira Garcia, Gustavo Goncalves Conti, Luiz Paulo Kowalski
Summary: The study analyzed data from 145 patients with T3 and T4a laryngeal cancer and found that primary tumor volume is significantly associated with rates of recurrence and survival, potentially serving as a promising prognostic indicator for these patients undergoing surgical treatment.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
(2021)
Article
Oncology
Justyna Durslewicz, Anna Klimaszewska-Wisniewska, Jakub Jozwicki, Paulina Antosik, Kamil Kozerawski, Dariusz Grzanka, Marcin Braun
Summary: MATR3 is a nuclear matrix protein involved in mRNA stabilization, nuclear retention of hyper-edited RNAs, and RNA splicing. This study investigates the expression levels and prognostic significance of MATR3 in early-stage non-small cell lung cancer (NSCLC) patients. The study found that the expression of MATR3 protein was significantly higher in tumor-adjacent tissue compared to cancer tissue, while MATR3 mRNA levels were significantly higher in tumor tissue compared to control lung tissues. High levels of MATR3 mRNA were associated with worse overall survival of NSCLC patients. Further investigation is needed to understand the biological and prognostic value of MATR3 as a potential prognostic marker in early-stage NSCLC patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Pathology
Ying Wang, Xuebing Yan, Xiao Qu, Jingxian Mao, Jiaxin Wang, Mengxue Yang, Min Tao
Summary: In this study, researchers found that the expression of DNA repair-related protein TOPBP1 was significantly increased in colorectal cancer (CRC), and high TOPBP1 expression was associated with poor prognosis. TOPBP1 promotes the malignant progression of CRC through MAP3K3-induced epithelial-mesenchymal transition (EMT).
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Oncology
Boris Duchemann, Marie Naigeon, Edouard Auclin, Roberto Ferrara, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, Francois-Xavier Danlos, Laura Mezquita, Caroline Caramella, Aurelien Marabelle, Benjamin Besse, Nathalie Chaput
Summary: The balance between circulating CD8(+)PD-1(+) and CD4(+)PD-1(+) is associated with the effectiveness of immune checkpoint blockade therapy in non-small cell lung cancer patients. PERLS in the blood sample can be a new indicator for evaluating treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Alessio Cortellini, Biagio Ricciuti, Victor R. Vaz, Davide Soldato, Joao Alessi, Filippo G. Dall'Olio, Giuseppe L. Banna, Sethupathi Muthuramalingam, Samuel Chan, Margarita Majem, Aida Piedra, Giuseppe Lamberti, Elisa Andrini, Alfredo Addeo, Alex Friedlaender, Francesco Facchinetti, Teresa Gorria, Laura Mezquita, Delphine Hoton, Lacroix Valerie, Frank Aboubakar Nana, James Artingstall, Charles Comins, Massimo Di Maio, Andrea Caglio, Judith Cave, Hayley McKenzie, Thomas Newsom-Davis, Joanne S. Evans, Marcello Tiseo, Antonio D'Alessio, Claudia A. M. Fulgenzi, Benjamin Besse, Mark M. Awad, David J. Pinato
Summary: In patients with advanced NSCLC, baseline BMI does not appear to affect clinical outcomes from first-line chemoimmunotherapy combinations, unlike what was observed with chemotherapy-free ICI-based regimens.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Psychology, Clinical
Laura Mezquita, Adrian J. Bravo, Angelina Pilatti, Generos Ortet, Manuel I. Ibanez
Summary: The present study tested the measurement invariance of the CUDIT-R among college students from seven countries and across gender groups. The results showed that the CUDIT-R is a suitable measure to assess cannabis-related problems in different countries and gender groups. The study also provided reliability and validity evidence for the scale.
ADDICTIVE BEHAVIORS
(2022)
Article
Oncology
Mariona Riudavets, Virginie Lamberts, Damien Vasseur, Edouard Auclin, Mihaela Aldea, Cecile Jovelet, Charles Naltet, Pernelle Lavaud, Anas Gazzah, Frank Aboubakar, Miriam Dorta, Jordi Remon, Etienne Rouleau, Maud Ngocamus, Claudio Nicotra, Ludovic Lacroix, Benjamin Besse, Laura Mezquita, David Planchard
Summary: This study aimed to evaluate the detection of EGFR mutations by Crystal digital PCR (cdPCR) liquid biopsy and explore its clinical utility in advanced non-small cell lung cancer (NSCLC). The results showed that cdPCR is a sensitive method for detecting both sensitizing and resistance EGFR mutations. Positive cdPCR results were more likely to occur in cases with high tumor burden. Therefore, cdPCR is a low-cost approach for EGFR mutation detection that can guide the treatment of NSCLC.
CLINICAL LUNG CANCER
(2022)
Article
Psychology, Clinical
Victoria O. Chentsova, Adrian J. Bravo, Laura Mezquita, Angelina Pilatti, Lee Hogarth
Summary: This study examines the indirect associations between internalizing symptoms (specifically depressive and social anxiety symptoms) and problematic social networking sites (SNS) use via rumination among a cross-cultural sample. The results show that higher internalizing symptoms are associated with more problematic SNS use through higher ruminative thinking. Problem-focused thoughts have a significant impact on the relationship between depressive and social anxiety symptoms and problematic SNS use. The findings suggest the importance of exploring the role of rumination in determining and comparing problematic SNS use cross-culturally in further longitudinal and experimental work.
ADDICTIVE BEHAVIORS
(2023)
Article
Oncology
Garcia-Corbacho Javier, Indacochea Alberto, Gonzalez Navarro E. Azucena, Victoria Ivan, Moreno Debora, Pesantez David, Angelats Laura, Modrego-Sanchez Andrea, Sanfeliu Esther, Castillo Oleguer, Blasco Paula, Mezquita Laura, Vinolas Nuria, Nogue Miquel, Galvan Patricia, Adamo Barbara, Baste Neus, Sauri Tamara, Juan Manel, Prat Aleix, Schettini Francesco
Summary: Immune-checkpoint inhibitors (ICI) have dramatically changed the way we treat cancer, but there is still a need for better patient selection. In this observational study, 146 patients with metastatic cancer were recruited and their blood samples and archived tissues were analyzed to assess factors that may predict response to ICI. The study found that baseline LIPI score, immunotherapy-naive status, cancer type, and previous radiotherapy were the most important clinical factors independently associated with immunotherapy outcomes.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, Giacomo Massa, Giulio Metro, Isabelle Monnet, Patricia Gomez Iranzo, Fabrizio Tabbo, Emilio Bria, Florian Guisier, Damien Vasseur, Colin R. Lindsay, Santiago Ponce-Aix, Sophie Cousin, Fabrizio Citarella, Vincent Fallet, Jose Nicolas Minatta, Anna Eisert, Hortense de Saint Basile, Clarisse Audigier-Valette, Laura Mezquita, Antonio Calles, Giannis Mountzios, Marco Tagliamento, Jordi Remon Masip, Judith Raimbourg, Safae Terrisse, Alessandro Russo, Diego Cortinovis, Philippe Rochigneux, David James Pinato, Alessio Cortellini, Camille Leonce, Anas Gazzah, Maria-Rosa Ghigna, Roberto Ferrara, Filippo Gustavo Dall'Olio, Francesco Passiglia, Vienna Ludovini, Fabrice Barlesi, Enriqueta Felip, David Planchard, Benjamin Besse
Summary: This retrospective study analyzed 218 cases of non-small cell lung cancer (NSCLC) with RET fusion mutations and found that RET inhibitors can significantly improve patient survival, while immune checkpoint inhibitors may also be effective in some patients.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Edouard Auclin, Jose Benitez-Montanez, Marco Tagliamento, Francesca Parisi, Teresa Gorria, Rosario Garcia-Campelo, Naomi Dempsey, David J. Pinato, Roxana Reyes, Victor Albarran-Artahona, Filippo Dall'Olio, Davide Soldato, Lizza Hendriks, Frank Aboubakar Nana, Marion Tonneau, Rafael Lopez-Castro, Ernest Nadal, Suzanne Kazandjian, Thierry Muanza, Felix Blanc-Durand, Elizabeth Fabre, Natalia Castro, Hugo Arasanz, Adrien Rochand, Benjamin Besse, Bertrand Routy, Laura Mezquita
Summary: This study evaluated the efficacy of second-line chemotherapy treatments in patients with metastatic NSCLC after progression following first-line chemo-immunotherapy. Results showed that 52% of patients were resistant to first-line chemo-immunotherapy, and among second-line treatments, 46% received taxane monotherapy.
Article
Oncology
Alexander Drilon, Joshua C. Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M. Gadgeel, D. Ross Camidge, Anthonie J. van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S. Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R. Soglia, Nancy E. Kohl, James R. Porter, Matthew D. Shair, Viola Zhu, Monika A. Davare, Aaron N. Hata, Henry E. Pelish, Jessica J. Lin
Correction
Oncology
Javier Garcia-Corbacho, Alberto Indacochea, Azucena E. Gonzalez Navarro, Ivan Victoria, Debora Moreno, David Pesantez, Laura Angelats, Andrea Modrego-Sanchez, Esther Sanfeliu, Oleguer Castillo, Paula Blasco, Laura Mezquita, Nuria Vinolas, Miquel Nogue, Patricia Galvan, Barbara Adamo, Neus Baste, Tamara Sauri, Manel Juan, Aleix Prat, Francesco Schettini
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Oncology
Juan Bautista Blaquier, Sandra Ortiz-Cuaran, Biagio Ricciuti, Laura Mezquita, Andres Felipe Cardona, Gonzalo Recondo
Summary: The landscape of targeted therapies for EGFR-mutant NSCLC is expanding, but resistance to treatment is a challenge. Understanding and using DNA sequencing has led to the development of innovative strategies to overcome or prevent resistance in the clinical setting.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Matthieu Roulleaux Dugage, Victor Albarran-Artahona, Juan Carlos Laguna, Nathalie Chaput, Stephane Vignot, Benjamin Besse, Laura Mezquita, Edouard Auclin
Summary: Immunotherapy with immune-checkpoint inhibitors (ICIs) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). It has shown promising results in early NSCLC, especially with neoadjuvant multimodality approaches. However, biomarkers for predicting response to ICIs in early-stage NSCLC are lacking. PD-L1 expression and tumor mutational burden seem to correlate with better response rates and survival. Other promising approaches include blood-based ratios, microbiota, and baseline intratumoral TCR clonality. Circulating tumor DNA could help in selecting best candidates for adjuvant ICIs and monitoring tumor response.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Pauline Parent, Edouard Auclin, Anna Patrikidou, Laura Mezquita, Nieves Martinez Chanza, Clement Dumont, Alejo Rodriguez-Vida, Casilda Llacer, Rebeca Lozano, Raffaele Ratta, Axel S. Merseburger, Cora N. Sternberg, Giulia Baciarello, Emeline Colomba, Alina Fuerea, Benjamin Besse, Yohann Loriot, Pernelle Lavaud
Summary: This report studied the LIPI score in population with unresectable urothelial cancer treated with immune checkpoint inhibitor (ICI). LIPI score was associated with clinical outcomes for ICI in several tumor types. Prognostic groups were classified based on LIPI score, and poor LIPI was associated with poorer overall survival (OS). LIPI score could identify a subset of patients with poorer outcomes in patients with good prognosis according to the Bellmunt score.
Editorial Material
Oncology
Marco Tagliamento, Jordi Remon, David Planchard, Benjamin Besse
EUROPEAN JOURNAL OF CANCER
(2023)
Meeting Abstract
Oncology
Yoann Pradat, Julien Viot, Konstantin Gunbin, Andrei Iurchenko, Marc Deloger, Luigi Cerbone, Guillaume Grisay, Loic Verlingue, Veronique Scott, Stefan Michiels, Antoine Hollebecque, Gerome Jules-Clement, Antoine Laine, Luc Friboulet, Laura Mezquita, Yohann Loriot, Benjamin Besse, Fabrice Andre, Paul-Henry Cournede, Daniel Gautheret, Sergey Nikolaev